Literature DB >> 105807

Animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids.

G C Todd, W J Griffing, W R Gibson, D M Morton.   

Abstract

Neurotoxicity is the major side effect occurring during the clinical use of vincristine (VCR). Animal models predictive of potential neurotoxicity would be very useful in the preclinical development of new vinca compounds. To simulate conditions in which neurotoxicity is produced during the clinical use of VCR, experimental animals (except the guinea pig) were given the test compounds by the iv route over a prolonged time period. Doses were selected based on the production of leukopenia. Vindesine (VDS), a chemically modified vinblastine (VBL) product, was compared with VCR and VBL in animal studies. Definite neurotoxic manifestations developed when VCR was given to chickens, cats, and monkeys. The administration of VDS or VBL did not produce neurotoxic signs in these species. The mouse, rat, dog, and guinea pig were not found to be useful models. Thus, it would appear the chicken, cat, and monkey would be appropriate animal models for the preclinical testing of new vinca compounds.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 105807

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.

Authors:  V S Sethi; P Surratt; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors.

Authors:  C Focan; R Olivier; S Le Hung; R Bays; J J Claessens; H Debruyne
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 3.  Recognition and treatment of nongonococcal urethritis in clinical practice.

Authors:  O O Isiadinso
Journal:  J Natl Med Assoc       Date:  1980-09       Impact factor: 1.798

4.  Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.

Authors:  David N Phalen; Angela Frimberger; Stephen Pyecroft; Sarah Peck; Colette Harmsen; Suzanneth Lola; Beatriz de Mello Mattos; Kong M Li; Andrew J McLachlan; Antony Moore
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.